Vistusertib
- Generic Name
- Vistusertib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C25H30N6O3
- CAS Number
- 1009298-59-2
- Unique Ingredient Identifier
- 0BSC3P4H5X
- Background
Vistusertib is under investigation for the treatment of Advanced Gastric Adenocarcinoma.
- Associated Conditions
- -
- Associated Therapies
- -
A trial of vistusertib and paclitaxel for ovarian cancer that has come back (OCTOPUS)
140 women in a trial received either paclitaxel with vistusertib or paclitaxel with a placebo. No difference was found in cancer growth, survival, or treatment effectiveness between the groups. Severe side effects were more common in the vistusertib group, including increased infection risk and fatigue. Adding vistusertib to paclitaxel did not improve ovarian cancer treatment. Low PTEN levels were linked to longer cancer growth intervals in the vistusertib group, suggesting further study is needed.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath